%0 Journal Article
%T A short-term follow-up of glycemic and body weight changes in diabetic patients who replaced dipeptidyl peptidase-4 inhibitors with the sodium-glucose cotransporter 2 inhibitor empagliflozin
%A Brend Ray-Sea Hsu
%A Chung-Huei Huang
%A Yu-Yao Huang
%J Archive of "Annals of Saudi Medicine".
%D 2018
%R 10.5144/0256-4947.2018.420
%X Sodium-glucose cotransporter 2 inhibitors (SGLT2is, gliflozins) are associated with lower all-cause mortality than other anti-diabetic agents in patients with type 2 diabetes. In patients who may benefit from SGLT2is, but cannot add them to a dipeptidyl peptidase-4 inhibitor (DPP4i, gliptin) treatment for various reasons, replacement of the DPP4i with a SGLT2i may be considered
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302983/